Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases.
暂无分享,去创建一个
Lisa St John-Williams | Lisa St. John-Williams | J. Walsh | T. Fujishita | John S Walsh | L. St. John-Williams | M Jane Cox Rosemond | Toshiro Yamaguchi | Toshio Fujishita | Toshiro Yamaguchi | M. C. Rosemond
[1] L. Amzel,et al. Structures of mammalian cytosolic quinone reductases. , 2000, Free Radical Biology & Medicine.
[2] A. Atalla,et al. Carbonyl reduction of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by cytosolic enzymes in human liver and lung. , 2000, Cancer letters.
[3] Nouri Neamati,et al. Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga , 2002 .
[4] A. Skalka,et al. The retroviral enzymes. , 1994, Annual review of biochemistry.
[5] A. Somogyi,et al. Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol. , 2000, British journal of clinical pharmacology.
[6] J B Houston,et al. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[7] T. Penning,et al. The aldo-keto reductase superfamily homepage. , 2003, Chemico-biological interactions.
[8] A. Hara,et al. Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. , 2002, Biological & pharmaceutical bulletin.
[9] Amy S. Espeseth,et al. Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[10] J. Houston,et al. Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat. , 1999, The Journal of pharmacology and experimental therapeutics.
[11] R. Gulick. New antiretroviral drugs. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[12] M. Martin,et al. Molecular organization of the AIDS retrovirus , 1985, Cell.
[13] D. Hazuda,et al. Inhibition of HIV-1 Ribonuclease H by a Novel Diketo Acid, 4-[5-(Benzoylamino)thien-2-yl]-2,4-dioxobutanoic Acid* , 2003, The Journal of Biological Chemistry.
[14] M. Lewis,et al. Comparative anatomy of the aldo-keto reductase superfamily. , 1997, The Biochemical journal.
[15] Erik De Clercq. New developments in anti-HIV chemotherapy. , 2001 .
[16] A. Fauci,et al. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. , 1988, Science.
[17] Y. Kallberg,et al. Coenzyme-based functional assignments of short-chain dehydrogenases/reductases (SDRs). , 2003, Chemico-biological interactions.
[18] L. Amzel,et al. Structure and mechanism of cytosolic quinone reductases. , 1999, Biochemical Society transactions.
[19] T. Tracy,et al. Atypical kinetic profiles in drug metabolism reactions. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[20] Marc C Nicklaus,et al. Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S). , 2003, Molecular pharmacology.
[21] T. Nakayama,et al. Structural and functional comparison of two human liver dihydrodiol dehydrogenases associated with 3 alpha-hydroxysteroid dehydrogenase activity. , 1992, The Biochemical journal.
[22] Haiching Ma,et al. Structure-function aspects and inhibitor design of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) , 2001, Molecular and Cellular Endocrinology.
[23] K. Neet,et al. Transients and cooperativity. A slow transition model for relating transients and cooperative kinetics of enzymes. , 1972, The Journal of biological chemistry.
[24] D. Ross,et al. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. , 2000, Chemico-biological interactions.
[25] H. Jörnvall,et al. Forms and functions of human SDR enzymes. , 2001, Chemico-biological interactions.
[26] H. Thijssen,et al. Stereoselective acetonyl side chain reduction of warfarin and analogs. Partial characterization of two cytosolic carbonyl reductases. , 1992, Drug metabolism and disposition: the biological fate of chemicals.
[27] Yun Tang,et al. Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. , 2002, Journal of medicinal chemistry.
[28] E. Maser,et al. Purification, characterization and NNK carbonyl reductase activities of 11beta-hydroxysteroid dehydrogenase type 1 from human liver: enzyme cooperativity and significance in the detoxification of a tobacco-derived carcinogen. , 2003, Chemico-biological interactions.
[29] A. Hara,et al. Kinetic studies of the inhibition of a human liver 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase isozyme by bile acids and anti-inflammatory drugs. , 1995, Biological and Pharmaceutical Bulletin.
[30] K. Nill,et al. High-affinity stereoselective reduction of the enantiomers of ketotifen and of ketonic nortriptyline metabolites by aldo-keto reductases from human liver. , 2000, Biochemical pharmacology.
[31] S. Ekins,et al. Autoactivation and activation of the cytochrome P450s. , 1998, International journal of clinical pharmacology and therapeutics.
[32] H. Shiraishi,et al. Roles of the C-terminal domains of human dihydrodiol dehydrogenase isoforms in the binding of substrates and modulators: probing with chimaeric enzymes. , 1998, The Biochemical journal.
[33] A. D. Rodrigues,et al. Enzyme kinetics of cytochrome P450-mediated reactions. , 2012, Current drug metabolism.
[34] J. Walsh,et al. The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes. , 2002, Chemico-biological interactions.
[35] U. Oppermann,et al. Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions. , 2000, Toxicology.
[36] A. Atalla,et al. Purification and characterization of oxidoreductases-catalyzing carbonyl reduction of the tobacco-specific nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human liver cytosol , 2000, Xenobiotica; the fate of foreign compounds in biological systems.
[37] D. Cohen,et al. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[38] N. Bachur,et al. Adriamycin metabolism in man. Evidence from urinary metabolites. , 1976, Drug metabolism and disposition: the biological fate of chemicals.
[39] Hara,et al. Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. , 1995, Biochemical pharmacology.
[40] A. Rettie,et al. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.